Previous close | 0.0400 |
Open | 0.0100 |
Bid | 0.0000 |
Ask | 0.0000 |
Strike | 50.00 |
Expiry date | 2024-01-19 |
Day's range | 0.0100 - 0.0400 |
Contract range | N/A |
Volume | |
Open interest | N/A |
Sign up now to see all the the picks and follow the 'Beat the S&P 500' strategy for up to 60% off for a limited time only!
Pfizer (NYSE: PFE), known for its billion-dollar coronavirus products -- the vaccine Comirnaty and the treatment Paxlovid -- saw its shares drop about 40%. This includes Pfizer's newer programs and what they may deliver in the future, as well as the company's valuation today. Is Pfizer a buy right now -- or a stock to avoid?
One stock I'm considering letting go is pharma giant Pfizer (NYSE: PFE). Here are two other issues driving me toward hitting the "sell" button on this pharma stock. Since Albert Bourla took over as CEO in 2019, Pfizer has been on a buying spree.